全文获取类型
收费全文 | 4128篇 |
免费 | 276篇 |
国内免费 | 55篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 92篇 |
妇产科学 | 33篇 |
基础医学 | 720篇 |
口腔科学 | 65篇 |
临床医学 | 339篇 |
内科学 | 856篇 |
皮肤病学 | 309篇 |
神经病学 | 291篇 |
特种医学 | 180篇 |
外科学 | 517篇 |
综合类 | 52篇 |
一般理论 | 1篇 |
预防医学 | 148篇 |
眼科学 | 100篇 |
药学 | 376篇 |
中国医学 | 46篇 |
肿瘤学 | 319篇 |
出版年
2024年 | 4篇 |
2023年 | 21篇 |
2022年 | 89篇 |
2021年 | 132篇 |
2020年 | 80篇 |
2019年 | 97篇 |
2018年 | 126篇 |
2017年 | 112篇 |
2016年 | 164篇 |
2015年 | 208篇 |
2014年 | 266篇 |
2013年 | 314篇 |
2012年 | 402篇 |
2011年 | 366篇 |
2010年 | 232篇 |
2009年 | 197篇 |
2008年 | 247篇 |
2007年 | 207篇 |
2006年 | 200篇 |
2005年 | 165篇 |
2004年 | 152篇 |
2003年 | 114篇 |
2002年 | 96篇 |
2001年 | 39篇 |
2000年 | 42篇 |
1999年 | 24篇 |
1998年 | 45篇 |
1997年 | 35篇 |
1996年 | 38篇 |
1995年 | 36篇 |
1994年 | 20篇 |
1993年 | 12篇 |
1992年 | 20篇 |
1991年 | 14篇 |
1990年 | 12篇 |
1989年 | 24篇 |
1988年 | 18篇 |
1987年 | 19篇 |
1986年 | 12篇 |
1985年 | 7篇 |
1984年 | 5篇 |
1983年 | 7篇 |
1982年 | 4篇 |
1981年 | 6篇 |
1980年 | 6篇 |
1978年 | 5篇 |
1977年 | 5篇 |
1973年 | 4篇 |
1971年 | 2篇 |
1968年 | 2篇 |
排序方式: 共有4459条查询结果,搜索用时 15 毫秒
991.
The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid‐Lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low‐Density Lipoprotein 下载免费PDF全文
Tae‐Eun Kim Dongseong Shin Namyi Gu Byung Hwa Jung Jayoun Kim Young Min Cho Kyung‐Sang Yu Joo‐Youn Cho 《Basic & clinical pharmacology & toxicology》2017,121(3):195-201
Rosuvastatin is an HMG‐CoA reductase inhibitor widely used for treating hypercholesterolaemia. We investigated whether genetic polymorphisms in solute carrier organic anion transporter 2B1 (SLCO2B1) affect the lipid‐lowering effect of rosuvastatin in healthy adults with elevated low‐density lipoprotein (LDL). This study included 18 volunteers with LDL levels above 130 mg/dL. Rosuvastatin (20 mg) was administered once a day for 8 weeks. Blood samples were drawn before and after the 8‐week treatment to measure changes in lipid levels. The presence of single nucleotide polymorphisms (SNPs) of SLCO2B1 (c.935G>A and c.1457C>T), SLCO1B1 (c.521C>T, c.388A>G and c.‐11187G>A) and ABCG2 (c.421C>A) was determined by genotyping. Responses to rosuvastatin were compared between wild‐type and variant genotypes using permutation test on each polymorphism. In volunteers with SLCO2B1 c.935G>A (rs12422149) variant, rosuvastatin was less effective at lowering LDL (mean % decrease: GG 62.8% GA 50.6% AA 49.3%, p = 0.012) and apoprotein B (mean % decrease: GG 52.1% GA 42.8% AA 42.8%, p = 0.036). Regarding SLCO2B1 c.1457C>T (rs2306168) SNP, there was no significant difference between wild‐type and variant genotypes. This study demonstrated that SLCO2B1 c.935G>A (rs12422149) polymorphism influenced the lipid‐lowering effects of rosuvastatin in volunteers with hypercholesterolaemia. 相似文献
992.
Youn Zoo Cho So Yeon Park Eun Hee Choi Soon Koo Baik Sang Ok Kwon Young Ju Kim Seung Hwan Cha Moon Young Kim 《Clinical and molecular hepatology》2015,21(2):165-174
Background/Aims
The therapeutic effect of transarterial chemoembolization (TACE) against hepatocellular carcinoma (HCC) is usually assessed using multidetector computed tomography (MDCT). However, dense lipiodol depositions can mask the enhancement of viable HCC tissue in MDCT. Contrast-enhanced ultrasonography (CEUS) could be effective in detecting small areas of viability and patency in vessels. We investigated whether arterial enhancement in CEUS after treatment with TACE can be used to detect HCC viability earlier than when using MDCT.Methods
Twelve patients received CEUS, MDCT, and gadoxetic-acid-enhanced dynamic magnetic resonance imaging (MRI) at baseline and 4 and 12 weeks after TACE. The definition of viable HCC was defined as MRI positivity after 4 or 12 weeks.Results
Eight of the 12 patients showed MRI positivity at 4 or 12 weeks. All patients with positive CEUS findings at 4 weeks (n=8) showed MRI positivity and residual viable HCC at 4 or 12 weeks. Five of the eight patients with positive CEUS findings at 4 weeks had negative results on the 4-week MDCT scan. Four (50%) of these eight patients did not have MRI positivity at 4 weeks and were ultimately confirmed as having residual HCC tissue at the 12-week MRI. Kappa statistics revealed near-perfect agreement between CEUS and MRI (κ=1.00) and substantial agreement between MDCT and MRI (κ=0.67).Conclusions
In the assessment of the response to TACE, CEUS at 4 weeks showed excellent results for detecting residual viable HCC, which suggests that CEUS can be used as an early additive diagnosis tool when deciding early additional treatment with TACE. 相似文献993.
Youn Jeong Kim Yoon Hee Jun Ho Joong Choi Young-Kyoung You Dong Goo Kim Jong Young Choi Seung Kew Yoon Sang Il Kim 《Transplantation proceedings》2019,51(8):2766-2770
BackgroundEnterococcus species are a common cause of bacteremia in liver transplant recipients. Vancomycin-resistant enterococci (VRE) have become an important cause of nosocomial infection. In this study, we analyzed the incidence, antibiotic resistance, and outcomes of enterococcal bacteremia in living donor liver transplant recipients and the risk factors for VRE.Patients and MethodsThis single-center, retrospective review included 536 patients who underwent liver transplant between January 2008 and December 2017.ResultsAmong 536 patients, 42 (7.8%) experienced a total of 58 enterococcal bacteremic episodes (37 Enterococcus faecium, 17 Enterococcus faecalis, 2 Enterococcus casseliflavus, 1 Enterococcus. avium, and 1 Enterococcus raffinosus). Most cases of enterococcal bacteremia (46/58, 79.3%) occurred within 6 months after transplant; among the 26 cases of VRE bacteremia, 50% occurred within 1 month after transplant. E. faecium isolates had the highest rate of vancomycin resistance (25/37, 67.5%), whereas all E. faecalis isolates were susceptible to vancomycin. According to multivariate analysis, post-transplant dialysis (odds ratio, 3.95; 95% CI, 1.51–10.34; P = .005) and length of post-transplant hospital stay (odds ratio, 1.03; 95% CI, 1.009–1.04; P = .004) were significantly associated with VRE bacteremia. One-year mortality was 31% (13/42) among recipients with enterococcal bacteremia, 5.0% (20/384) among nonbacteremic patients, and 11.1% (10/90) among patients with nonenterococcal bacteremia (P < .001).ConclusionIn this study, enterococcal bacteremia showed high incidence in liver transplant recipients, especially with vancomycin resistance, occurred in early period after transplant, and was associated with increased mortality. High rates of resistance to vancomycin warrant further efforts to manage enterococcal infection in liver transplant recipients at our center. 相似文献
994.
Young-Hwan Ahn Heirim Lee Do Young Kim Hye Won Lee Su Jong Yu Young Youn Cho Jeong Won Jang Byoung Kuk Jang Chang Wook Kim Hee Yeon Kim Hana Park Hyo Jung Cho Bumhee Park Soon Sun Kim Jae Youn Cheong 《Gut and liver》2021,15(3):410
Background/AimsThis study was performed to evaluate the efficacy of direct-acting antivirals (DAAs) in Korean patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and to investigate the risk factors associated with HCC recurrence.MethodsA total of 100 patients with HCV-related HCC, who were treated with DAAs between May 2015 and December 2016, were recruited from seven university hospitals in Korea. Claim data of 526 patients with HCC obtained from the Health Insurance Review and Assessment Service in South Korea were used for external validation of the results.ResultsAmong the 100 patients, 88% achieved a sustained virological response (SVR) 12 weeks after the end of DAA therapy (SVR12), and 37% experienced HCC recurrence after DAA therapy. Short last HCC treatment durability (<12 months) before DAA commencement was independently associated with HCC recurrence (hazard ratio [HR], 2.89; p=0.011). In the nationwide validation cohort, 20.3% of the patients experienced HCC recurrence. The last HCC treatment with a noncurative method, a short last HCC treatment durability (<12 months), and a longer total duration of HCC treatment (≥18 months) were independently related with HCC recurrence (HR 3.73, p<0.001; HR 3.34, p<0.001; and HR 1.74, p=0.006; respectively).ConclusionsDAA therapy showed an acceptable SVR12 rate in patients with HCV-related HCC. Short last HCC treatment durability (<12 months) was associated with HCC recurrence after DAA therapy. This finding suggests that the last HCC treatment durability is an important predictor of HCC recurrence after DAA therapy. (Gut Liver 2021;15-419) 相似文献
995.
Jinyoung Youn Ji Sun Kim Munhyang Lee Jeehun Lee Hakjae Roh Chang-Seok Ki Jin Whan Choa 《JOURNAL OF CLINICAL NEUROLOGY》2014,10(1):50-54
Background and Purpose
Given the diverse phenotypes including combined non-dyskinetic symptoms in patients harboring mutations of the gene encoding proline-rich transmembrane protein 2 (PRRT2), the clinical significance of these mutations in paroxysmal kinesigenic dyskinesia (PKD) is questionable. In this study, we investigated the clinical characteristics of PKD patients with PRRT2 mutations.Methods
Familial and sporadic PKD patients were enrolled and PRRT2 gene sequencing was performed. Demographic and clinical data were compared between PKD patients with and without a PRRT2 mutation.Results
Among the enrolled PKD patients (8 patients from 5 PKD families and 19 sporadic patients), PRRT2 mutations were detected in 3 PKD families (60%) and 2 sporadic cases (10.5%). All familial patients with a PRRT2 gene mutation had the c.649dupC mutation, which is the most commonly reported mutation. Two uncommon mutations (c.649delC and c.629dupC) were detected only in the sporadic cases. PKD patients with PRRT2 mutation were younger at symptom onset and had more non-dyskinetic symptoms than those without PRRT2 mutation. However, the characteristics of dyskinetic movement did not differ between the two groups.Conclusions
This is the first study of PRRT2 mutations in Korea. The presence of a PRRT2 mutation was more strongly related to familial PKD, and was clinically related with earlier age of onset and common non-dyskinetic symptoms in PKD patients. 相似文献996.
Choi SH Kwak SH Youn BS Lim S Park YJ Lee H Lee N Cho YM Lee HK Kim YB Park KS Jang HC 《The Journal of clinical endocrinology and metabolism》2008,93(8):3142-3148
CONTEXT: Women with previous gestational diabetes mellitus (pGDM) are at high risk of developing type 2 diabetes mellitus in the future. The role of adipokines in women with pGDM has not been established. OBJECTIVE: We investigated whether circulating adipokine concentration is associated with abnormal glucose homeostasis in women with pGDM. DESIGN, SETTING, PATIENTS, AND MAIN OUTCOME MEASURES: We measured the plasma concentrations of retinol-binding protein-4 (RBP4), transthyretin (TTR), and adiponectin and metabolic parameters in four groups of women who exhibited normal glucose tolerance (NGT) during a previous pregnancy (NP, n = 17), NGT after GDM (GDM-NGT, n = 72), impaired glucose tolerance after GDM (GDM-IGT, n = 60), and type 2 diabetes after GDM (GDM-DM, n = 8). RESULTS: Plasma RBP4 concentration was significantly higher in women with GDM-DM, GDM-IGT, and GDM-NGT than in those with NP. RBP4 concentration correlated positively with TTR concentration; fasting plasma glucose, insulin, and triglyceride concentrations; blood pressure; abdominal fat area; and homeostasis model assessment of insulin resistance. Plasma TTR concentration was elevated in women with GDM-DM compared with other groups. In contrast, adiponectin concentration was lowest in the GDM-DM group and correlated inversely with parameters of insulin resistance. Resistin concentration was higher only in the GDM-NGT and GDM-IGT groups, whereas leptin did not differ between groups. Plasma RBP4 and adiponectin concentrations were inversely correlated. CONCLUSIONS: The severity of glucose intolerance in women with pGDM is associated with high RBP4 and low adiponectin concentrations. 相似文献
997.
Impact of left ventricular ejection fraction and medication adherence on major adverse cardiac events during the first year after successful primary percutaneous coronary interventions 下载免费PDF全文
Youn‐Jung Son PhD RN Sook Kyung Shim MSc RN Sun Young Hwang MSc RN Ji Hun Ahn MD Hye Yon Yu PhD RN 《Journal of clinical nursing》2016,25(7-8):1101-1111
998.
Comparison of scoring systems for nonvariceal upper gastrointestinal bleeding: a multicenter prospective cohort study 下载免费PDF全文
999.
Combined effect of Hashimoto's thyroiditis and BRAFV600E mutation status on aggressiveness in papillary thyroid cancer 下载免费PDF全文
1000.